# NXC-201 (formerly HBI0101) Multiple Myeloma

> **NCT04720313** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hadassah Medical Organization** · enrollment: 160 (estimated)

## Conditions studied

- Dose Escalation and Safety

## Interventions

- **DRUG:** NXC-201 (formerly HBI0101)

## Key facts

- **NCT ID:** NCT04720313
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720313, "NXC-201 (formerly HBI0101) Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04720313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*